29.11.2022 - 01.12.2022Revere Hotel Boston Common, 200 Stuart Street, 02116 Boston, Massachusetts, USA
Time: 09:55 - 16:40
Kongressthemen The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders.
Speakers: Allison Goldfine, Director, Translational Medicine Cardiometabolic Disease, Novartis, Andrew Billin, Senior Director Biomarker Sciences, Gilead, and more.